We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Mutations Identified for Cowden Syndrome

By LabMedica International staff writers
Posted on 03 Jan 2013
Two new genes have been identified that are associated with Cowden syndrome (CS), an under-diagnosed condition that carries high risks of breast, thyroid, and other cancers.

The discovery of these genes will promote diagnosis and clinical management of CS while also assisting in predictive genetic testing and genetic counseling for a disease that is difficult to recognize and is characterized by small, noncancerous growths. More...


Scientists at the Cleveland Clinic (Cleveland, OH, USA) performed genetic sequencing on DNA from individuals with CS who have none of the known genetic alterations associated with CS. State-of-the-art technology was used to identify a high prevalence of mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) and the alpha serine/threonine-protein kinase (AKT1) genes, which are involved in cancer-related signaling pathways.

Germline mutations in the phosphatase and tensin homolog (PTEN) gene were found to cause 85% of CS when data from tertiary academic centers was analyzed. However, prospective data from the community over the last 12 years has revealed a 25% PTEN mutation frequency. PTEN is the phosphatase that has been implicated in a heritable cancer syndrome and subsequently in multiple sporadic cancers and developmental processes.

The investigators found that 8 of 91 (8.8%) unrelated CS individuals without germline PTEN mutations carried 10 germline PIK3CA mutations and 2 (2.2%) had AKT1 mutations. These mutations result in significantly increased phosphorylation of AKT on the activation residue Thr308 (P-Thr308-AKT) and increased cellular phosphatidylinositol (3,4,5)-triphosphate (PIP3). These results suggest that PIK3CA and AKT1 are CS susceptibility genes.

Charis Eng, MD, PhD, who is the Founding Director of the Lerner Research Institute's Genomic Medicine Institute (Cleveland, OH, USA) said, “Gene-enabled risk assessment and management begins with the identification of all the genes that, when mutated, account for as many or all the individuals with a particular syndrome, in this case CS. We started with only PTEN, and now we know that succinate dehydrogenase complex, subunit B, iron sulfur (SDHB/D), killin, p53-regulated DNA replication inhibitor (KLLN), PIK3CA, and AKT1 account for CS. Each also brings differing risks of breast, thyroid, and other cancers, and so this discovery directly aids genetic counseling and clinical management.” Cowden syndrome is a rare autosomal dominant inherited disorder characterized by multiple tumor-like growths called hamartomas and an increased risk of certain forms of cancer. The study was published on December 13, 2012, in the American Journal of Human Genetics.

Related Links:

Cleveland Clinic
Lerner Research Institute's Genomic Medicine Institute



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.